Compugen Ltd. is a clinical-stage therapeutic discovery and development company that uses Unigen, an AI/ML-powered computational platform, to identify novel drug targets and develop cancer immunotherapy treatments. The company operates in the immuno-oncology space with a pipeline of proprietary and partnered antibodies targeting immune checkpoints and related mechanisms, including COM701 (an anti-PVRIG antibody in clinical development) and licensed programs with AstraZeneca and Gilead. Compugen generates revenue through upfront licensing fees, milestone payments, research funding, and royalties from its drug development partnerships, while maintaining early-stage research programs to expand its target discovery capabilities.